Equity · Healthcare
VRDN
NASDAQViridian Therapeutics (VRDN)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.
- Market cap
- 2.8B USD
- Revenue, year to Dec 2025
- 70.8M USD
- 52-week range
- 13.31 USD – 34 USD
- Avg volume
- 413.5K
as of Aug 20, 2026
Have Viridian Therapeutics (VRDN) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, Viridian Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); none has bought on the open market since 11 May 2026.
Form 4, 90 days to 10 Nov 2026, newest reported trade 19 Aug 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 19 Aug 2026 | Tousignant JenniferChief Legal Officer | Sell | 14,212 | 348K USD |
2 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 19 Aug 2026 | Tousignant JenniferChief Legal Officer | Option exercise | 10,000 | 144K USD |
| 14 Aug 2026 | Tripuraneni RadhikaChief Medical Officer | Option exercise | 40,000 | 528K USD |
Which funds hold Viridian Therapeutics (VRDN)?
0 of the 45 institutional funds we track reported a Viridian Therapeutics position for the quarter ended 30 Sep 2026; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Exited |
What has been filed or recorded for Viridian Therapeutics (VRDN)?
The filings we hold for Viridian Therapeutics, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 13 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 6,593 shares | 121K USD notional · 0.006% of shares out |
| 30 Sep 2026 | Fails to deliver | Shares failed to deliver | 3,669 shares | 73K USD notional · 0.003% of shares out |
| 30 Sep 2026 | Financials | Total assets | 1.0B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 580.7M USD | at period end |
| 31 Dec 2025 | Financials | Revenue | 70.8M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −342.6M USD | fiscal year |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −1.15 USD | |
| 30 Jun 2024 | Quarterly earnings | Q2 2024 reported | EPS −1.02 USD | |
| 31 Mar 2024 | Quarterly earnings | Q1 2024 reported | EPS −0.79 USD | |
| 31 Dec 2023 | Annual report | FY 2023 reported | EPS −5.31 USD | |
| 30 Sep 2023 | Quarterly earnings | Q3 2023 reported | EPS −1.09 USD | |
| 30 Jun 2023 | Quarterly earnings | Q2 2023 reported | EPS −1.27 USD | |
| 31 Mar 2023 | Quarterly earnings | Q1 2023 reported | EPS −1.61 USD | |
| 31 Dec 2022 | Annual report | FY 2022 reported | EPS −4.05 USD |
What do people ask about Viridian Therapeutics (VRDN)?
What did Viridian Therapeutics shares close at?25.00
Viridian Therapeutics closed at 25.00 USD on 20 Aug 2026, unchanged on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Viridian Therapeutics’ market cap?2.8B
Viridian Therapeutics is worth 2.8B USD by market value as of 20 Aug 2026, which is the share price times the shares on issue from its SEC filings.
What is Viridian Therapeutics’ revenue?70.8M
Viridian Therapeutics reported revenue of 70.8M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Viridian Therapeutics insiders bought or sold shares recently?1 sale
In the 90 days to 10 Nov 2026, Viridian Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); none has bought on the open market since 11 May 2026. A further 2 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Viridian Therapeutics?0 of 45
0 of the 45 funds we track reported a Viridian Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
When did Viridian Therapeutics last report earnings?−1.15
Viridian Therapeutics last reported earnings on 30 Sep 2024 for Q3 2024, with EPS of −1.15 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings